Business
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company remains on track to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stag
About this update from Protara Therapeutics, Inc.
[{"type":"image","alt":"Protara Therapeutics","displaySize":"","headline":null,"caption":"Protara Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/859264115c175ddb8556462fe6954a72"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/isLqAMYwKjK9tTz.2PYBLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0OA--/https://media.zenfs.com/en/globenewswire.com/859264115c175ddb8556462fe6954a72","width":300,"height":106},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/isLqAMYwKjK9tTz.2PYBLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0OA--/https://media.zenfs.com/en/globenewswire.com/859264115c175ddb8556462fe6954a72","width":300,"height":106}},"lazy":false},{"type":"text","content":" TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients","length":191,"tagName":"p"},{"type":"text","content":"Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events","length":101,"tagName":"p"},{"type":"text","content":"Company remains on track to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026","length":105,"tagName":"p"},{"type":"text","content":"NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive updated 12-month data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) non-muscle invasive bladder cancer (NMIBC). These results in Bacillus Calmette-Guérin (BCG)-Naïve NMIBC patients will be featured today during a poster session at the American Urological Association (AUA) 2026 Annual Meeting in Washington, D.C.","length":633,"tagName":"p"},{"type":"text","content":"“Today’s presentation demonstrates TARA-002’s impressive 12-month durability data and excellent safety profile for patients with BCG-Naïve NMIBC,” said Mark Tyson, M.D., Professor of Urology, Mayo Clinic Phoenix, and ADVANCED-2 study investigator. “The NMIBC patient community faces a critical unmet need for safe, effective and bladder-sparing treatment options for ...